TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

SYMJEPI

EPINEPHRINE Adrenergic alpha-Agonists
Cardiovascular Approved 2017-06-15
Jump to: Indications Approvals Trials Competitors Similar Safety Patents
2
Indications
--
Phase 3 Trials
8
Years on Market

Details

Status
Prescription
First Approved
2017-06-15
Routes
INTRAMUSCULAR, SUBCUTANEOUS
Dosage Forms
SOLUTION

Companies

ADAMIS PHARMS CORP
Active Ingredient: EPINEPHRINE

SYMJEPI Approval History

Loading approval history...

What SYMJEPI Treats

2 indications

SYMJEPI is approved for 2 conditions since its original approval in 2017. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Hypotension
  • Septic Shock
Source: FDA Label

Drugs Similar to SYMJEPI

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

ADRENACLICK
EPINEPHRINE
2 shared
IMPAX
Shared indications:
HypotensionSeptic Shock
ADRENALIN
EPINEPHRINE
2 shared
PH HEALTH
Shared indications:
HypotensionSeptic Shock
EPINEPHRINE (AUTOINJECTOR)
EPINEPHRINE
2 shared
Teva
Shared indications:
HypotensionSeptic Shock
EPIPEN JR.
EPINEPHRINE
2 shared
Viatris
Shared indications:
HypotensionSeptic Shock
XYLOCAINE W/ EPINEPHRINE
EPINEPHRINE
2 shared
Fresenius Kabi
Shared indications:
HypotensionSeptic Shock
AKOVAZ
EPHEDRINE SULFATE
1 shared
EXELA PHARMA
Shared indications:
Hypotension
CORPHEDRA
EPHEDRINE SULFATE
1 shared
PH HEALTH
Shared indications:
Hypotension
EMERPHED
EPHEDRINE SULFATE
1 shared
NEXUS
Shared indications:
Hypotension
LEVOPHED
NOREPINEPHRINE BITARTRATE
1 shared
Pfizer
Shared indications:
Hypotension
NOREPINEPHRINE BITARTRATE
NOREPINEPHRINE BITARTRATE
1 shared
Fresenius Kabi
Shared indications:
Hypotension
NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE
NOREPINEPHRINE BITARTRATE
1 shared
LONG GROVE PHARMS
Shared indications:
Hypotension
NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE
NOREPINEPHRINE BITARTRATE
1 shared
SAGENT
Shared indications:
Hypotension
PHENYLEPHRINE HYDROCHLORIDE
PHENYLEPHRINE HYDROCHLORIDE
1 shared
MEITHEAL
Shared indications:
Hypotension
VASOPRESSIN
VASOPRESSIN
1 shared
Dr. Reddy's
Shared indications:
Hypotension
VASOPRESSIN IN DEXTROSE 5%
VASOPRESSIN
1 shared
GLAND
Shared indications:
Hypotension
VASOPRESSIN IN SODIUM CHLORIDE 0.9%
VASOPRESSIN
1 shared
Baxter
Shared indications:
Hypotension
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...
⭐

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

ClinicalTrials.gov ↗ Pro

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

SYMJEPI FDA Label Details

Pro

Indications & Usage

FDA Label (PDF)

Epinephrine is a non-selective alpha and beta adrenergic agonist indicated to increase mean arterial blood pressure in adult patients with hypotension associated with septic shock. 1.1 Hypotension associated with Septic Shock Epinephrine Injection USP, 1 mg/10 mL (0.1 mg/mL) is indicated to increase mean arterial blood pressure in adult patients with hypotension associated with septic shock.

SYMJEPI Patents & Exclusivity

Latest Patent: Oct 2036

Patents (4 active)

US11141540 Expires Oct 20, 2036
Source: FDA Orange Book

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

FDA Approval: NDA207534 → Label: DailyMed → Patents: FDA Orange Book → Trials: ClinicalTrials.gov →

Data sourced from official FDA and NIH databases. Click links to verify on original sources.